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Background: Plants from the genus Ocimum are used as folk medicine for treating various diseases including
inflammatory and immune-related diseases. Numerous reports have suggested plant extracts and their constituents
as possible anti-inflammatory agents. Here, in vitro evidence of Ocimum labiatum’s immune-enhancing and antioxidant
properties is presented for the first time.
Methods: The anti-inflammatory effect of O. labiatum ethanolic extract and an isolated diterpenoid was determined
using a cytometric bead array (CBA) technique. The effect on phytohemagglutinin (PHA)-induced nitric oxide (NO)
production in peripheral blood mononuclear cells (PBMCs) was also assessed. A battery of antioxidant assays were used
for detecting antioxidant activity while the anti-inflammatory mechanism was evaluated using an ELISA-based activator
protein (AP-1) (c-Jun) assay. Cytotoxicity was determined on TZM-bl and PBMCs using a tetrazolium dye and confirmed
by a novel label-free real-time assay.
Results: A 25 μg/mL non-cytotoxic concentration of O. labiatum extract significantly (p < 0.05) inhibited the production
of pro-inflammatory cytokines; IL-2, IL-4, IL-6 and IL-17A. Except for the dual acting pro- or anti-inflammatory cytokine,
IL-6, which was upregulated, a non-cytotoxic 50 μM concentration of the isolated labdane diterpenoid compound
significantly (p < 0.05) decreased the production of all the pro-inflammatory cytokines. In the anti-inflammatory pathway
studies, the compound also inhibited AP-1 significantly (p < 0.05) at 50 μM. The extract demonstrated strong, dose
dependent antioxidant activity with IC50 values ranging from 13 ± 0.8 to 54.86 ± 1.28 μg/mL while the terpene had no
antioxidant property. The extract and diterpenoid decreased the production of the inflammatory mediator NO, at
non-cytotoxic concentrations. The CC50 of the extract in TZM-bl and PBMCs was 62.6 ± 0.6 and 30.1 ± 0.4 μg/mL while
that of the compound was 112.6 ± 0.2 and 70 ± 0.4 μM respectively. The real time studies confirmed tetrazolium dye
assessed viability and also detected a unique growth pattern for the plant materials compared to untreated cells.
Conclusions: O. labiatum extract demonstrated promising anti-inflammatory and antioxidant properties while the
terpenoid showed anti-inflammatory but no antioxidant activity. The anti-inflammatory mechanism of the terpene was
a result of inhibition of AP-1. These data represents promising first steps towards the development of naturally derived
anti-inflammation drugs.
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The majority (60%) of approved drugs are either directly
isolated or derived from natural products [1]. Ocimum
labiatum, commonly known as ‘pink sage’, belongs to
the Lamiaceae family and is widely distributed in Southern
Africa [2]. The plant is indigenously used for medicinal
purposes, mostly antimicrobial [2,3]. Plants from the
Ocimum genus are used traditionally to alleviate various
disease symptoms such as pain, fever and inflammation,
and the pharmacological activities of some extracts of
these plants have been studied in vitro or in vivo without
identifying the bioactive components [4-7].
Lamiaceae plants are generally rich in terpenoids; a
diverse class of naturally occurring organic-chemicals
derived from five-carbon isoprene units. Plant isolates
containing terpenoids have been found to suppress nu-
clear factor kappa B (NF-κβ) signalling [8], a protein
complex linked to the pathogenesis of inflammatory dis-
eases, cancer, viral infection and autoimmune diseases
[8]. In another study, semisynthetic labdane diterpenoid
derivatives reportedly suppressed NF-κβ and nitric oxide
(NO) production in macrophages [9]. NO is an inflam-
matory molecule produced by inducible NO synthase in
macrophages and plays a role in immunoregulation
[10,11]. Inhibitors of NO might be of therapeutic im-
portance in preventing pathological conditions catalysed
by inflammation [9-11]. Investigations of labdane diter-
penoids suggest these compounds to have potential as
alternative treatment for inflammatory diseases and fur-
ther investigation is needed to identify the exact mech-
anism of action and pathways that are modulated by
these compounds. Two labdane diterpenoid compounds
were isolated from O. labiatum by Hussein et al. (2007)
one of which inhibited Mycobacterium tuberculosis and
the other demonstrated moderate anti-cancer properties
both in vitro [12].
Plants from the Lamiaceae family are considered to be
good sources of antioxidants due to the presence of high
concentrations of phenolic compounds [13,14]. Antioxi-
dants have the ability to dismutate reactive oxygen species
(ROS) which are produced by the oxidation processes in
various cells. Oxidative stress, caused by the accumulation
of ROS in animal tissues, is a major cause of cell damage
or death and is considered an instrumental process that
leads to various cancers and other diseases [15]. In addi-
tion, ROS in low concentrations act as significant cell sig-
nalling molecules and regulates the biological conditions
of cytokines, hormones and growth factors. High levels of
free radicals, however, overcome the normal cellular anti-
oxidant defences and end up being cytotoxic to the bio-
logical system [16]. These cumulative ROS are associated
with a number of diseases including chronic inflammatory
diseases [17-19]. ROS have also been reported to be in-
volved in the activation of NF-κβ by pro-inflammatorycytokines such as Tumour necrosis factor (TNF)-α [16].
Given the importance of activated NF-κβ in inflammatory
disease progression, suppression of this protein directly or
through inhibition of ROS or pro-inflammatory cytokines
preferably by antioxidants, remain therapeutically import-
ant because of the ability of the latter to combat patho-
genic chain reactions initiated by free radicals.
The activator protein 1 (AP-1) is another transcription
factor which regulates inflammatory cytokines and thus
is being targeted as a way of circumventing inflamma-
tion [20]. AP-1 consist of dimeric transcription factors
namely Jun, Fos and ATF subunits [21]. Inhibition of the
c-Jun component of AP-1 results in the prevention of
transcription of inflammatory genes and hence inflam-
matory cytokines since AP-1 is prevented from binding
to transcription factors in the nucleus [22].
The onset of common human diseases such as auto-
immunity and chronic infections is characterized by a
dysregulation of the T helper cell type 1 (Th1) and Th2
cytokine balance [23]. Interleukin (IL)-6 has been re-
ported to be responsible for Th17 cells induction to se-
crete IL-17, a pro-inflammatory cytokine [24]. Since
cytokines are central mediators in major inflammatory
diseases and impact one another’s production and action
[23], it is important to simultaneously measure more
than one cytokine from all 3 subsets; Th1/Th2/Th17.
This will allow for better assessment of immune and in-
flammation status with these proteins as potential indi-
cators in prognostic and drug discovery studies [23,25].
Although many species of the Ocimum genus have
been extensively investigated in vitro, this is not the case
with O. labiatum. In this study, O. labiatum was investi-
gated for anti-inflammatory properties through inhib-
ition or suppression of pro-inflammatory cytokines
using the human Th1/Th2/Th17 cytometric bead array
assay which allows for the quantification of multiple cy-
tokines in a single sample. The effect of O. labiatum on
NO production was also evaluated because there is on-
going research for potential anti-inflammatory agents
from nature due to adverse side effects and high costs of
existing anti-inflammatory drugs [26]. The antioxidant po-
tential of O. labiatum as well as the anti-inflammatory
pathway was also investigated.
Methods
Plant extraction and compound isolation
Fresh leaves (894.6 g) of O. labiatum were collected dur-
ing February (2012) from the Botanical garden of the
University of Pretoria. Plant identification was done in
the H.G.W.J Schweikerdt herbarium of the University and
a voucher specimen (117693) is kept in the herbarium.
Fresh leaves were blended in ethanol and filtered. The
filtrate was evaporated under reduced pressure at 50°C
using a rotary evaporator (Buchi, Flawil, Switzerland)
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lipophilic fraction. The ethyl acetate fraction was trans-
ferred to a pre-weighed vial and was evaporated to dry-
ness at room temperature. The dried extract was stored
in the dark at 4°C until use. The extract was weighed
out as needed and reconstituted in dimethyl sulfoxide
(DMSO) before each biological assay. Reconstituting in
DMSO surface sterilized the extract. Further dilutions to
the desired extract concentrations were done in either
cell culture media or buffer depending on the type of
biological assay performed.
The ethyl acetate fraction (31.1 g) was subjected to
column chromatography (Si gel 70–230 mesh) eluting
with hexane (1.5 L) then with hexane-ethyl acetate (9:1,
4:1, 7:3, 3:2, 1:1, 3:7; 1.5 L each) and finally with ethyl
acetate (1.5 L), collecting fractions of 500 mL each. The
last fraction, with 100% ethyl acetate, yielded a pure
compound in the form of white crystals (65 mg).
Labda-8(17),12E,14-triene-2R,18-diol (Figure 1): White
crystals (C20H32O2);
1H NMR (CDCl3, 500 MHz): δ 6.32
(1H, dd, J = 10.5, 17.5 Hz, H-14), 5.40 (1H, t, J = 6.0,
12.5 Hz, H-12), 5.05 (1H, d, J = 17.5 Hz, H-15a), 4.88
(1H, d, J = 11.0 Hz, H-15b), 4.86 (1H, d, J = 1.5 Hz,
H-17a), 4.49 (1H, d, J = 1.0 Hz, H-17b), 3.97 (1H, m,
H-2), 3.42 (1H, d, J = 11.0 Hz, H-18a), 3.18 (1H, d, J = 11
Hz, H-18b), 2.38 (1H, m, H-11a), 2.37 (1H, m, H-11b),Figure 1 Chemical structure of the labdane diterpenoid
Labda-8(17), 12E,14-triene-2R,18-diol.2.03 (2H, m, H-7), 1.88 (1H, d, J = 10.5 Hz), 1.75 (3H, s,
H-16), 1.63 (2H, m, H-6), 1.47 (1H, dd, J = 2.5, 12.5 Hz,
H-5), 1.41 (2H, d, J = 11.5 Hz, H-3), 1.05 (2H, t, J = 11.5,
23.0 Hz, H-1), 0.81 (3H, s, H-20), 0.80 (3H, s, H-19); 13C
NMR (CDCl3, 125 MHz): δ 147.4 (C, C-8), 141.5 (CH,
C-14), 133.6 (C, C-13), 133.4 (CH, C-12), 110.0 (CH2,
C-15), 108.5 (CH2, C-17), 71.5 (CH2OH, C-18), 65.5
(CHOH, C-2), 56.8 (CH, C-9), 47.9 (CH2, C-1), 47.5
(CH, C-5), 44.6 (CH2, C-3), 40.7 (C, C-10), 39.4 (C, C-4),
37.5 (CH2, C-7), 23.5 (CH2, C-6), 23.3 (CH2, C-11), 18.5
(CH3, C-19), 15.8 (CH3, C-20), 11.8 (CH3, C-16); MS m/z
304.2402 (calculated for C20H32O2 [M
+] 304.2402).
The 1H and 13C NMR spectra of compound 1 displayed
resonances for an exocyclic methylene group H-17 at δ
4.86 (1H, d, 1.5) and 4.49 (1H, d, 4.49) both attached to
carbon at δ 108.5. The spectra further showed the pres-
ence of C-9 side chain which was identical to those re-
ported data by Hussein et al., 2007. The 1H NMR spectra
showed the presence of methine proton in a cyclohexane
ring at δ 3.97 (1H, m), placed between two methylene sub-
stituents at δ 1.05 (2H, t, 11.5, 23.0) and 1.41 (2H, d, 11.5),
suggesting C-2 was attached to a hydroxyl substituent,
possibly as part of the labdane hydrocarbon skeleton. The
spectroscopic data showed an AB system at δ 3.42 and
3.18 (1H, d, J = 11.0 each) of hydroxymethylene group at-
tached to quaternary carbon C-4 (δ 71.5). The position of
the hydroxyl group at the C-18 (δ 71.5) was further con-
firmed by the HMBC spectrum which showed correlation
between the hydoxymethylene protons and the C-3 (δ
44.6), C-4 (δ 39.4), C-5 (δ 47.5) and C-19 (δ 18.5).
The 13C NMR and DEPT spectra showed the presence
of twenty carbon signals. These included, four quater-
nary carbons C-4, C-8, C-10 and C-13 at δ 39.4, 147.4,
40.7 and 133.6 respectively; one oxymethine carbon C-2
at δ 65.5; four methine carbons C-5, C-9, C-12 and C-14
at δ 47.5, 56.8, 133.4 and 141.5 respectively; one oxy-
methylene carbon C-18 at δ 71.5; seven methylene car-
bons C-1, C-3, C-6, C-7, C-11, C-15 and C-17 at δ 47.9,
44.6, 23.5, 37.5, 23.2,110.0 and 108.5 respectively; and
three methyl carbons C-16, C-19 and C-20 at δ 11.8,
18.5 and 15.8 respectively as shown in Table 1.
The COSY spectrum depicted mostly correlations of the
adjacent protons H-11a,b; H-14a,b; H-17a,b and H-18a,b.
From the NMR spectroscopic data the molecular formula
of compound 1 was determined to be C20H32O2, corre-
sponding to a theoretical exact mass of 304.24. The MS
data showed a molecular ion M+ peak at m/z 304.24 con-
firming the structure of compound 1. The 1H and 13C
NMR spectroscopic data for compound 1 compared well
with literature data [12].
Viability of TZM-bl cells using MTT
The effect of O. labiatum extract and isolated com-
pound on the viability of TZM-bl cells was determined
Table 1 NMR spectral assignments for compound 1
Carbon
number
δC δH, J (Hz) HMBC COSY
C-1 (CH2) 47.9 1.05 (2H, t, 11.5, 23.0)
C-2 (CHOH) 65.5 3.97 (1H, m)
C-3 (CH2) 44.6 1.41 (2H, d, 11.5)
C-4 (C) 39.4
C-5 (CH) 47.5 1.47 (1H, dd, 2.5, 12.5)
C-6 (CH2) 23.5 1.63 (2H, m)
C-7 (CH2) 37.5 2.03 (2H, m)
C-8 (C) 147.4
C-9 (CH) 56.8 1.88 (1H, d, 10.5)
C-10 (C) 40.7
C-11 (CH2) 23.2 2.38 (1H, m) H-11b
2.37 (1H, m) H-11a
C-12 (CH) 133.4 5.40 (1H, t, 6.0, 12.5) C-9, C-11,
C-14, C-16
C-13 (C) 133.6
C-14 (CH) 141.5 6.32 (1H, dd, 10.5, 17.5) C-13, C-16
C-15 (CH2) 110.0 5.05 (1H, d, 17.5) C-13, C-14 H-14
4.88 (1H, d, 11.0) H-14
C-16 (CH3) 11.8 1.75 (3H, s)
C-17 (CH2) 108.5 4.86 (1H, d, 1.5) C-7, C-9 H-17b
4.49 (1H, d, 1.0) H-17a
C-18 (CH2OH) 71.5 3.42 (1H, d, 11.0) C-3, C-4,
C-5, C-19,
H-18b
3.18 (1H, d, 11.0) H-18a
C-19 (CH3) 18.5 0.80 (3H, s)
C-20 (CH3) 15.8 0.81 (3H, s)
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tabolized by viable cells from 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) solution (Sigma,
MO, USA) as previously reported [27]. TZM-bl cells
were maintained in complete Dulbecco’s Modified Eagle
Medium (DMEM; Sigma, MO, USA); containing antibi-
otics and foetal bovine serum. Cells were plated in 96
well plates (Corning Incorporated, Corning, USA) at 1 ×
104 cells per well and were treated with crude extract
at final concentrations of 100, 50, 25, 12.5, 6.25 and
3.125 μg/mL. In the case of the compound, the final con-
centrations were 3.125-100 μM. Viability was determined
after 72 h incubation (37°C, 90% humidity, 5% CO2). Con-
trol wells included a negative control (cells and medium
only), blank control for the extract (extract and medium
only), a toxicity control auranofin; a known toxic com-
pound with antitumour activity [28], and a DMSO control
(percentage of DMSO similar to extracts in cells to ensure
that this solvent did not cause cell death). The plates were
read at 550 nm using a microtiter plate reader (MultiskanAscent; Thermo Labsystems; MA, USA), a reference wave-
length of 690 nm was used and the percentage viability
was calculated relative to untreated control cells. Fifty per-
cent cytotoxic concentration (CC50) of the extract and
compound was obtained using Graphpad Prism (Graph-
pad Software Inc. CA, USA). This was computed as the
concentration of the extract/compound that reduced cell
viability by 50% when compared to controls.
Viability of PBMCs using MTS
Ethical approval for obtaining blood samples from con-
senting donors was granted by the Faculties of Natural and
Agricultural Sciences and Health Sciences Ethics Com-
mittees (EC080506-019; 163/2008, University of Pretoria,
South Africa). Freshly isolated healthy peripheral blood
mononuclear cells (PBMCs) were suspended in complete
RPMI 1640 (Sigma, MO, USA) medium (containing anti-
biotics and foetal bovine serum). Cells were then stimu-
lated with phytohemagglutinin-protein (PHA-P, 4 μg/mL),
plated in 96 well plates (Corning Incorporated, Corning,
USA) at 1 × 105 cells per well and treated with the extract
and compound at final concentrations of 100, 50, 25, 12.5,
6.25 and 3.125 μg/mL. The number of viable cells was de-
tected after 72 h using 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt (MTS) solution (Promega Corporation, WI, USA).
Control wells included a toxicity control auranofin and
the plates were read at 492 nm (reference wavelength of
690 nm). The percentage viability was calculated relative
to an untreated control of cells only and the CC50 values
were determined using Graphpad Prism (Graphpad Soft-
ware Inc. CA, USA).
Real time cell analysis
Confirmatory cytotoxicity analysis for the crude extract
and isolated compound was performed using a real time
cell electronic sensing (RT-CES) device, xCELLigence
(Roche Diagnostics, MA, Germany) to monitor prolifer-
ation of the TZM-bl cells in the presence of the extract
and isolated compound. A detailed procedure was fol-
lowed as previously described [29]. The xCELLigence
system monitors cellular events in real time without the
incorporation of labels by measuring electrical imped-
ance across interdigitated gold micro-electrodes inte-
grated on the bottom of special tissue culture plates.
Increasing attachment of cells to the electrodes increases
electrode impedance which is displayed as cell index
(CI) [30,31]. Cell titration was carried out as recom-
mended by the manufacturer in order to determine an
optimal cell number that reaches an index of ±1 after 24 h,
before treatment with the samples. Each well was seeded
with 10,000 cells, which was the ideal cell number ob-
tained from the titration. The CC50 of O. labiatum extract
obtained with an MTT assay was tested alongside 10 μM
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were also included as controls. Cells were first allowed to
adhere for 24 h before treating them with extracts. The
cellular effects of the extracts were monitored for 72 h
and CI values were recorded. The compound was applied
in the same manner. One concentration of the compound,
112.6 μM, CC50 determined with MTT was also moni-
tored for its effect in real time for 72 h.
Antioxidant assays
The antioxidant potential of the extract and terpene
were investigated using four different antioxidant assays
since antioxidant mechanisms could include different re-
actions with radical species. For these assays, all reagents
were obtained from Sigma Aldrich (Missouri USA) un-
less stated otherwise. Ascorbic acid was used as the posi-
tive control for all these assays at concentrations ranging
from (0.078 μg/mL to 100 μg/mL).
DPPH antioxidant assay
The potential antioxidant activity of O. labiatum extract
and Labda-8(17),12E,14-triene-2R,18-diol was assessed
on the basis of the scavenging ability of the test samples
towards a stable 2,2-diphenyl-1-picrylhydrazyl (DPPH)
free radical. Test samples were prepared at a starting
concentration of 100 μg/mL after mixing with 90 μM
DPPH ethanol solution. A series of concentrations were
tested for the samples in order to determine the 50% in-
hibitory concentration (IC50). Samples were incubated
with DPPH in the dark for 30 min at room temperature.
Absorbance values were measured at 550 nm (Multiskan
Ascent; Thermo Labsystems; MA, USA) and converted
into percentage of antioxidant activity [32]. Background
control was samples in ethanol only and a DPPH only
control was also include. IC50 was determined using
Graphpad Prism (Graphpad Software Inc. CA, USA). The
percentage inhibition was calculated by using the formula:
100 – ½ðSample Optical density ODð Þ
– Sample background ODÞ= DPPH only ODð Þ  100
Ferric reducing antioxidant power (FRAP)
The FRAP assay was performed a previously described,
with minor modifications [33,34]. The terpenoid com-
pound and extract (0.781 to 100 μg/mL) was dissolved in
DMSO (5%) and further diluted with double distilled de-
ionized water.
Freshly prepared FRAP reagent (20 mL acetate buffer,
2 mL TPTZ solution, 2 mL ferric chloride solution and
2.4 mL autoclaved dH2O) was heated to 37°C. A reagent
blank, ascorbic acid calibrations (0.078 μg/mL to 10 μg/mL)
and samples were submitted to the FRAP assay as follows:
8 μl of sample and 240 μl FRAP reagent were added to 96well plates, mixed and incubated for 10 minute. Absorb-
ance readings were obtained at 595 nm and plotted as
(Sample Optical density (OD) – Sample background OD-
blank) against compound or extract concentration.
Cupric reducing antioxidant capacity (CUPRAC)
This assay was performed as previously described [35].
The terpenoid compounds and extract concentrations
ranged from 0.781 μg/mL to 100 μg/mL and that for as-
corbic acid ranged from 0.078 μg/mL to 10 μg/mL. The
sample (50 μl) and 150 μl CUPRAC reagent consisting
of 10 mM Copper(II)chloride, 7.5 mM neucoproine
(AEC Amersham) and ammonium acetate buffer (1% (v/v)
acetic acid, 0.1 M ammonium acetate, pH7) were mixed
and incubated for 30 minutes at room temperature before
absorbance readings were obtained at 450 nm. An experi-
ment blank and sample background controls were also in-
cluded. The data was plotted as (Sample Optical density
(OD) – Sample background OD-blank) against compound
or extract concentration.
Crocin bleaching assay using 2,2′-azobis
(2-amidonopropane) hydrochloride (AAPH)
Reagents: PBS (27 mM KCl, 18 mM KH2PO4, 1.4 M NaCl,
0.1 M Na2HPO4 and autoclaved dH2O), 20 μM crocin so-
lution (crocin dissolved in 30% methanol), AAPH solution
(5 mg/mL AAPH dissolved in 1x PBS).
This assay was performed according to a previously
described method [36]. Fifty microliters of the terpenoid
compound and extract (0.78 μg/mL to 100 μg/mL) and
ascorbic acid (0.078 μg/mL to 10 μg/mL) were added to
100 μl crocin solution and 100 μl of AAPH solution.
These were mixed and incubated for 1 hour at room
temperature before absorbance readings were obtained
at 450 nm. The absorbance readings were plotted as
(Sample Optical density (OD) – Sample background OD-
blank) against compound or extract concentration.
Cytokine quantitation using cytometric bead array (CBA)
Ethical approval for obtaining blood samples from con-
senting donors was granted by the Faculties of Natural
and Agricultural Sciences and Health Sciences Ethics
Committees (EC080506-019; 163/2008, University of
Pretoria, South Africa). Sample preparation: Blood sam-
ples were taken from healthy volunteers; 9 individuals
for extract and 14 for compound. Freshly isolated PBMCs
stimulated with PHA-P (4 μg/mL), were seeded at 1 × 106
cells/well in order to get enough cytokine produced for
quantitative detection. Incubation of the cells with non-
cytotoxic concentrations of the extract (25 μg/mL) and
compound (50 μM) was done for 24 h. The supernatant
was collected and stored at −20°C until testing.
Quantitation: Cytokine levels were analysed in the tis-
sue culture supernatant using a BD CBA human Th1/
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CBA kit simultaneously measured IL-2, IL-4, IL-6, IL-10,
TNF, interferon gamma (INF-ɣ) and IL-17A protein levels
in a single sample using a FACSArray Bioanalyzer (BD
Biosciences, CA, USA). The assay was performed accord-
ing to the manufacturer’s instructions. Briefly, the super-
natant was thawed and 50 μl of each sample was mixed
with the cytokine capture beads and the detector reagent,
phycoerythrin (PE)-conjugated detection antibodies, to
form sandwich complexes. The intensity of PE fluores-
cence of each sandwich complex reveals the concentration
of that cytokine [25]. The limits of detection for each cyto-
kine was as follow: 2.6 pg/mL for IL-2, 4.9 pg/mL for IL-4,
2.4 pg/mL for IL-6, 4.5 pg/mL for IL-10, 3.8 pg/mL for
TNF, 3.7 pg/mL for IFN-ɣ and 18.9 pg/mL for IL-17A.
AP-1 (c-Jun) inhibition studies
The AP-1 group of transcription factors binds to the en-
hancer/promoter region of various cytokine genes in ac-
tivated cells [37]. The extract and isolated compound
were also evaluated to determine inhibition of the c-Jun
component of AP-1 as an indication of prevention of
transcription of inflammatory genes [22]. The Abcam c-Jun
(Ps73) ELISA kit (Abcam®, Cambridge, UK) was used in
the detection of PHA-P induced AP-1 from PBMCs and
the assay performed according to the manufacturer’s
protocol. PBMCs (1 × 106 cells/mL) pretreated with or
without the extract and diterpenoid compound were col-
lected and washed with phosphate buffered saline. The
cells were then lysed and antibody mix was added and in-
cubated for 1 h in a microplate. The microplate was
washed before the substrate was added for colour develop-
ment. A stop solution was added to stop the reaction after
10 min and the fluorescence signal obtained at 544/590
nm using a Fluoroskan Ascent® plate reader (Labsystems,
Helsinki, Finland).
Nitrite and nitrate detection by colorimetric assay
The effect of extract and isolated compound on NO pro-
duction was studied using an NO assay colorimetric kit
(Calbiochem, CA, USA). In aqueous solution, NO is rap-
idly converted to nitrate and nitrite. Hence, for accurate
determination of the total NO generated, both nitrate
and nitrite levels must be monitored. Spectrophotometric
quantitation of nitrite using only the Griess reagent does
not measure nitrate. Therefore, the NADH-dependent en-
zyme nitrate reductase is used to convert the nitrate to ni-
trite prior to quantitation using the Griess reagent. NO
was measured from PBMCs by plating cells in 96 well
plates at 2.0 × 105 cells/well. Cells were pre-incubated for
1 h with non-cytotoxic concentrations of the crude extract
(25 μg/mL) and labdane diterpenoid (50, 25 and 10 μM)
before stimulating for NO with a non-cytotoxic concen-
tration of PHA-P, 25 μg/mL and further incubating for24 h. After the 24 h incubation, cell culture supernatant
(50 μl) was collected and incubated with 1 U/μl of nitrate
reductase in the presence of 0.2 mM NADH and 50 mM
MOPS buffer, pH 7.0. After 20 min, Griess reagent was
added and further incubated for 5 min at room tem-
perature. The colour was read at 550 nm (Multiskan As-
cent; Thermo Labsystems; MA, USA). A standard curve
was generated, using freshly prepared 0–100 μM potas-
sium nitrate dissolved in assay buffer, to quantitate un-
known nitrite in samples.Statistical analysis
Data for all experiments is presented as the mean ±
standard deviation (n = 3-6). Since cytokine profiles vary
from person to person, the cytokine concentrations ob-
tained for each individual were log transformed in order
to standardize the data and make it more comparable
[25,38]. Significant differences were estimated using
Graphpad Prism 5 (Graphpad Software Inc. CA, USA)
and Student’s t test for unpaired observations. A p < 0.05
was considered significant.Results
Cytotoxicity
The CC50 of crude O. labiatum extract was 62.6 ± 0.6
μg/mL for TZM-bl cells and 30.1 ± 0.4 μg/mL in PBMCs
determined by viability dye MTT and MTS respectively.
The PBMCs (1 × 105 cells/well) used in this study did not
adequately metabolize the viability dye MTT but properly
metabolized MTS which is why the latter dye was used in
the PBMC analyses and MTT for TZM-bl assessments.
Tetrazolium dyes are metabolized differently by different
cell types. Considerable evidence indicates that the reduc-
tion of MTS occurs at the cell surface or at the level of the
plasma membrane via trans-plasma membrane electron
transport and not inside a cell as is the case with MTT
[39]. It is therefore possible that MTT was unable to prop-
erly penetrate the membrane of PBMCs for proper intra-
cellular metabolism and MTS which is metabolized on the
cell-surface was easily metabolized by these mononuclear
cells.
Cytotoxicity of the crude extract was confirmed with
RT-CES. RT-CES monitored the effect of the extract on
cell viability (Figure 2A), in real-time and confirmed the
CC50 value obtained with MTT. At 72 h post treatment,
the cell index for untreated cells (i) was 2.5. Cells treated
with 62.6 ± 0.6 μg/mL crude extract (CC50) resulted in
sample uptake (dip in cell growth before 24 h) and
metabolisation (hump) as demonstrated by the pattern
(ii) in Figure 2A. When the extract was properly metab-
olized, a reduction in cell viability was observed. About
50% (half of cell index value of control cells) of treated
cells remained viable at 72 hours of incubation.
AB
Figure 2 Real time monitoring of O. labiatum effect on the
viability of TZM-bl cells. Cells were exposed to 62.6 μg/mL of
extract (A) and 112.6 μM compound (B), which were the CC50
values determined in a tetrazolium dye assay. Auranofin (iii) was
used as a positive control for toxicity and caused cell death almost
from the time of addition until end of incubation period (72 h). A
unique growth pattern was observed in extract treated cells with
uptake in the first 48 hours followed by extract content being
metabolized by the cells resulting in an increase in cell index above
that of untreated cells which following prolonged exposure is
reduced to half cell index of control cells (i) at 72 h. RT-CES
demonstrated low cytotoxicity for compound treated cells 72 h
similar to that of untreated cells (i). For the compounds, uptake and
metabolism was similar to that of extract however, elevated cell
indices was maintained. Data was normalized against the time point
before extract addition.
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Labda-8(17),12E,14-triene-2R,18-diol, was also studied
using viability dyes MTT and MTS and it was found to
cause CC50s of 112.6 (34.3 μg/mL) ±0.2 and 70 (21.3
μg/mL) ±0.4 μM in TZM-bl and PBMCs respectively. The
cytotoxicity results were again confirmed with RT-CES
and these results are depicted in Figure 2B. Extract uptake
was observed before 24 h and metabolization of the sam-
ple resulted in a cell index value of 2.5 (ii) equivalent to
that of untreated control cells (i) at 72 h. RT-CES results
indicated that the CC50 of the compound obtained in
TZM-bl cells was not cytotoxic. Since RT-CES does not
involve the use of dye uptake or invasive methods to
measure cell status, this suggests this technique to be
more sensitive and accurate than MTT.
Antioxidant activity
The antioxidant effect of the test samples and ascorbic
acid obtained in the DPPH, FRAP, CUPRAC and crocinbleaching antioxidant assays are shown in Figure 3. For
all the assays, a dose dependent antioxidant activity was
observed for the extract with IC50 values of 13 ± 0.8
μg/mL, 53.62 ± 0.57, 47.32 ± 0.76 μg/mL and 54.86 ± 1.28
μg/mL respectively. The IC50 of ascorbic acid for the
individual assays was found to be 1.1 ± 0.03, 4.74 ± 0.60,
5.29 ± 0.03 and 6.69 ± 0.004 μg/mL respectively. For all
the assays, the labdane diterpenoid compound demon-
strated minimal to no antioxidant activity (<50%) for all
tested concentrations. Each assay was performed at least 5
times.
Effect of O. labiatum on cytokine production
Using the Cytometric Bead Array (CBA) human Th1/
Th2/Th17 cytokine kit (BD Biosciences, CA, USA), 7 cy-
tokines, IL-2, IL-4, IL-6, IL-10, TNF, INF-ɣ and IL-17A,
were analysed and quantified (Figure 4) following expos-
ure of PBMCs to plant material. O. labiatum crude ex-
tract was tested for anti-inflammatory properties at 25
μg/mL, a non-cytotoxic concentration. Cytokine produc-
tion in untreated PBMCs was used as a control for com-
parison to the production of cytokines in extract treated
PBMCs. The extract significantly (p < 0.05) decreased
the production of pro-inflammatory cytokines IL-2, IL-4,
IL-6 and IL-17A (Figure 4). For IL-10, INF-ɣ and TNF,
there was no significant (p > 0.05) difference detected in
untreated and extracted treated samples even though pro-
duction of those cytokines was lowered by the extract.
Effect of labda-8(17),12E,14-triene-2R,18-diol on
pro-inflammatory cytokines
The anti-inflammatory property of the purified labdane
diterpenoid was also studied using the CBA human
Th1/Th2/Th17 cytokine kit (BD Biosciences, CA, USA).
The compound was tested at 50 μM, a non-toxic con-
centration. The results obtained were compared to un-
treated cells. The compound was found to significantly
(p < 0.05) inhibit the production of all cytokines tested ex-
cept for IL-6 as illustrated in Figure 5. The production of
IL-6, which acts as both an anti- and pro-inflammatory
cytokine, was significantly (p < 0.05) up-regulated.
AP-1 inhibition by the labdane diterpenoid
The effect of the terpenoid (50 μM, 25 μM & 10 μM)
and the extract (25 μg/mL & 10 μg/mL) from the plant,
O. labiatum were tested for activity against c-Jun com-
ponent of AP-1 (n = 3) in PHA stimulated PBMCs. The
isolated compound significantly inhibited (p < 0.05) AP-
1 at 50 μM, but not at lower concentrations (Figure 6).
N-acetyl cysteine (NAC) which was used as the positive
control significantly inhibited AP-1 (p < 0.005). When
cells were co-treated with the terpenoid compound and
NAC, AP-1 was significantly stimulated (p < 0.05) at
50 μM, but not at lower concentrations suggesting that
A B
C D
Figure 3 Antioxidant effect of the O. labiatum extract (squares) and the isolated compound (triangles). The DPPH free radical scavenging,
the FRAP, cupric ion reducing activity, and crocin bleaching effect are shown in A, B, C and D respectively (n = 5-6.). The DPPH data is shown as
percentage inhibition. The IC50s for the extract were 13 ± 0.8 μg/mL, 53.62 ± 0.57, 47.32 ± 0.76 μg/mL and 54.86 ± 1.28 μg/mL respectively.
Ascorbic acid was used as positive control. The extract exhibited strong antioxidant activity while the diterpenoid compound did not. *tested in
two fold serial dilutions from 0.08-10 μg/mL.
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result of inhibition of the AP-1 pathway. Cells treated
with extract alone, as well as co-treated with extract and
NAC significantly (p < 0.05) stimulated AP-1 production
(Figure 6).
The effect of the compound on NF-kB from nuclear
extracts obtained from PBMCs was assessed using the





































Figure 4 Effects of a non-toxic concentration of O. labiatum
extract (25 μg/mL) on cytokine production in PBMCs. Cytokines
were quantified using the CBA kit and flow cytometry. Cytokine
concentrations were log transformed in order to make the data
comparable. Control treatments are represented by unshaded bars
whereas shaded bars represent extract treated samples. The crude
extract significantly (*p < 0.05) down-regulated levels of IL-2, IL-4,
IL-6 and IL-17A.Immunochemicals, Gilbertsville, PA, USA). The com-
pound had no appreciable effect on NF-kB at tested con-
centrations (data not shown).
NO levels in culture supernatant reduced by O. labiatum
and labdane diterpenoid
The effects of the extract and compound on PHA-
induced NO production in PBMCs were investigated by
quantitating nitrite in culture medium using the Griess
reaction. Unstimulated control cells, after 24 h of incu-
bation, produced a negligible amount of NO (<10 μM).
NO production in PHA stimulated cells was evident
(43 μM), while no significant levels of NO were detected
in the extract treated cells as illustrated in Figure 7. The
three concentrations tested for the labdane diterpenoid
compound significantly (p < 0.05) decreased the level of
NO in the cells with 25 μM of the compound being
more significant by reducing NO production to an un-
detectable level (Figure 7).
Discussion
The data obtained in this study suggest that O. labiatum
has immune supportive activities in addition to direct
antioxidant abilities. RT-CES proved to be a more sensi-
tive technique for detecting the effect of treatment on
cell viability. The technique detected a unique cell growth
pattern with extract and compound uptake and metabol-
ism which would not have been observed with viability
































Figure 5 Influence of labda-8(17),12E,14-triene-2R,18-diol on cytokine production in PBMCs as quantitated by CBA analysis and flow
cytometry. Cells were treated with a non-toxic concentration of 50 μM. Concentrations obtained of tested cytokines were log transformed in
order to make the data comparable. Control treatments are unshaded whereas compound treated cells are shaded. IL-6 was the only cytokine
that was up-regulated by the compound. The rest of the cytokines were significantly (*p < 0.05) down-regulated.
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since these methods only produce end-point data [40].
RT-CES, which is label-free, is able to capture important
effects such as the onset and rate of cytotoxicity as well as
other proliferation dynamics such as cytostasis [29]. Sensi-
tivity and accurate reflection using RT-CES has been at-
tributed to the ability of the technique to reflect on the
cell concentration and changes in cell morphology more
than viability dyes [40].
O. labiatum extract exhibited strong antioxidant activity
while the isolated labdane diterpenoid, Labda-8(17),12E,
14-triene-2R,18-diol, was not a good antioxidant suggest-





























Figure 6 The effect of the isolated compound and plant extract on A
tested for activity against the c-Jun component of AP-1 (n = 3) in PHA stim
50 μM. NAC (100 μg/mL) was used as positive control and significantly inh
production. At 25 μg/mL, the plant extract significantly stimulated AP-1 inthe presence of other compound(s). Non-terpenoid com-
pounds present in the extract such as flavonoids are more
likely to be responsible for antioxidant activity of plant ex-
tracts. Flavonoids, vitamins and polyphenols present in
plants are known to be powerful antioxidants [41].
The bead array technology used in this study allowed
for simultaneous detection of multiple cytokines in a
single sample. Because cytokines influence one another,
an imbalance in especially Th1 and Th2 cytokines can
lead to the pathogenesis of acute and chronic inflamma-
tory diseases [23]. Therefore, in studies where cytokines
are investigated as prognostic indicators [25], for thera-
peutic uses [42] or to assess their modulation by potential*
y
P-1. The isolated labdane diterpenoid (Lab) and the extract (OL) were
ulated PBMCs. Lab significantly (p < 0.05) inhibited AP-1 in PBMCs at
ibited AP-1 (a). Co-treatment with NAC resulted in stimulation of AP-1





















Figure 7 Inhibition of NO release by O. labiatum extract and labdane diterpenoid. PBMCs were pre-incubated for 1 h with the indicated
concentrations of the extract (OL) and compound (Lab) and then stimulated with 25 μg/mL PHA for 24 h. Untreated cells were used as a control.
Nitrite accumulation was measured with the Griess reagent. Extract and compound concentrations used were non-toxic. The results were
expressed as mean ± SD.
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cules representative of all 3 subsets (Th1/Th2/Th17) as
was done here.
Lamiaceae terpenoids have been documented to have
anti-inflammatory as well as antitumor effects [44]. The
isolation of the compound Labda-8(17),12E,14-triene-
2R,18-diol from O. labiatum was first reported in 2007
[12]. The only investigations done on the labdane diter-
penoid by these authors were anti-cancer testing against
breast cancer cells and an anti-tuberculosis study in
which the compound did not inhibit M. tuberculosis ac-
tivity at the highest concentration tested but showed
moderate cytotoxic effects against a breast cancer cell
line [12]. According to the literature, some labdane diter-
penoid compounds have been shown to possess immune
enhancing properties [9] which encouraged the investiga-
tion of these specific compounds for anti-inflammatory
and/or any immune supportive properties. The ability of
the isolated compound to down-regulate pro-inflammatory
cytokines, as was demonstrated here, can be of therapeutic
importance. The crude extract suppressed IL-2, IL-4, IL-6
and IL-17A while the compound suppressed all cytokines
tested except for IL-6 which was up-regulated. IL-6, which
can act as a pro- or anti-inflammatory cytokine, is part of a
network of cytokines that trigger or regulate immune re-
sponses and its increase by the compound in comparison
to the inhibitory effect on pro-inflammatory cytokines
contributes a beneficial balance to the host [25,45].
IL-2 and IL-17A have been reported to be responsible
for activating pathogenic inflammation in a number of
inflammatory skin diseases such as psoriasis [46,47].
High levels of IL-17A are reportedly associated withseveral chronic inflammatory diseases including rheuma-
toid arthritis and multiple sclerosis [48,49]. Therefore,
lowering these cytokines in such cases will be of clinical
use to the affected individual.
The down-regulation of the following cytokines IL-4,
IL-10 and TNF by the extract and compound can be of
general therapeutic significance. Over expression of
these cytokines has been linked to certain autoimmune
diseases as well as activation of pathogenic inflammation
[46,47]. Inhibiting IL-4 has been associated with alleviat-
ing allergies while the neutralization of IL-10 has been
linked to the reduction of helminth infection by restor-
ing the function of Th2 effector cells [50].
The production of TNF was drastically inhibited by
the labdane diterpenoid compound and this is a pro-
inflammatory cytokine associated with cancers and auto-
immune diseases [51]. TNF-α is regarded as a major
pro-inflammatory cytokine and there is a continuous
search for potential TNF-α inhibitors from natural prod-
ucts due to serious adverse side-effects of existing
protein-based inhibitors [26]. Overproduction of TNF-α
in rheumatoid arthritis patients has been linked to in-
creased ROS [52]. Inhibiting high levels of this cytokine
in such patients should also decrease ROS production
and consequently inflammation and cellular damage.
TNF-α has also been reported to induce NF-κβ produc-
tion [53] and this protein is inhibited by the presence of
antioxidants [54]. Here, O. labiatum showed antioxidant
activity and the ability to lower the production of TNF-α
meaning it could suppress NF-κβ production, further
supporting this plant being potentially useful in diseases
with pathogenesis enhanced by NF-κβ.
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AP-1 and MAPK. Inhibition of each pathway can result
in lower levels of specific cytokines such as IL-2 being
produced due to inflammation [55]. The isolated labdane
diterpenoid significantly inhibited c-Jun in the AP-1
pathway at 50 μM, indicating that inhibition of AP-1 is
the mechanism by which the isolated compound exhib-
ited its anti-inflammatory behaviour. The extract signifi-
cantly stimulated c-Jun in AP-1 suggesting that the
presence of other components in the extract could have
resulted in a synergistic stimulatory effect on AP-1
production.
The reduction of INF-ɣ by the labdane diterpenoid in
this study is suggestive of therapeutic potential. INF-ɣ is
reportedly involved in the inflammatory events under-
lying a vascular inflammatory condition called abdom-
inal aortic aneurysms (AAA) [56]. A large quantity of
INF-ɣ was reported [56] in supernatants from AAA ex-
plant cultures that suggested this cytokine to be involved
in AAA pathogenesis. Regulating the production of
INF-ɣ in AAA patients by reducing its production could
assist in alleviating that inflammatory condition. An-
other study [57] reported high production of INF-ɣ in
the brain and periphery to be involved in activating cer-
tain metabolic pathways which leads to an inflammation
cascade that results in aging and aging-associated med-
ical psychiatric disorders. Suppressing INF-ɣ in such
cases could be beneficial in avoiding/minimising psychi-
atric disorders associated with aging.
The anti-inflammatory properties of O. labiatum by
pro-inflammatory cytokines inhibition were supported
by the ability of the extract and labdane diterpenoid to
reduce the production of NO release. NO, which is
regarded as a potent inflammatory mediator, was inhib-
ited at concentrations that were not toxic indicating that
the NO actions of the extract and compound are not
attributable to cytotoxicity. The data presented here
confirms the ability of diterpenoids to also possess anti-
inflammatory abilities through NO inhibition as previ-
ously reported [9].
Antioxidation and anti-inflammation properties of
plants are routinely investigated and are considered to
be among the primary health benefits of natural prod-
ucts. In addition, antioxidative agents prevent the forma-
tion of a number of diseases including inflammatory
diseases. The anti-inflammatory properties of the O.
labiatum extract as well as that of the isolated com-
pound strongly suggest the immune enhancing proper-
ties of this plant.
Conclusion
The in vitro data obtained from this study demon-
strated for the first time that O. labiatum has potent
anti-inflammatory and antioxidant activity. This workencourages further investigations of O. labiatum’s poten-
tial use as complimentary medicine in anti-inflammatory
and antioxidant therapeutics and provides some empirical
data for the already prominent anecdotal use in traditional
medicines.
Abbreviations
AP-1: Activator protein 1; CBA: Cytometric bead array; CUPRAC: Cupric
reducing antioxidant capacity; DPPH: 2,2-diphenyl-1-picrylhydrazyl;
FRAP: Ferric reducing antioxidant power; IL: Interleukin;
MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; NF-κB: Nuclear factor kappa B; NMR: Nuclear
magnetic resonance; NO: Nitric oxide; PBMCs: Peripheral blood mononuclear
cells; ROS: Reactive oxygen species; RT-CES: Real time cell electronic sensing;
TNF: Tumour necrosis factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DM designed the study; PK conducted the research and wrote the first draft
of the manuscript. JJO did the compound’s structural elucidation and wrote
that section of the manuscript. RB and PF did three of the antioxidant assays
and the NF-kB and AP-1 assays and PF further contributed to the writing,
editing and updating the entire manuscript accordingly. DM edited and
revised the manuscript. All the authors approved and reviewed the data
interpretation and wording in the final draft of the manuscript.
Acknowledgments
This research was supported by the Southern African Biochemistry and
Informatics for Natural Products (SABINA), the Technology Innovation
Agency (TIA, South Africa), Margaret McNamara Memorial Fund (MMMF), the
Namibian Ministry of Education and the University of Pretoria. The School of
Chemistry, University of the Witwatersrand is thanked for running the NMR
spectra.
Author details
1Department of Biochemistry, Faculty of Natural and Agricultural Sciences,
University of Pretoria, Hatfield Campus, Pretoria 0002, South Africa.
2Molecular Sciences Institute, School of Chemistry, University of the
Witwatersrand, P.O. Box 2050, Johannesburg, South Africa. 3Present address:
Chemistry & Biochemistry department, Faculty of Science, University of
Namibia, Windhoek 9000, Namibia. 4Present address: Department of
Traditional Medicine, National Institute for Medical Research, P. O Box 9653,
Dar es Salaam, Tanzania. 5Present address: Department of Biochemistry,
Faculty of Sciences, University of Johannesburg, P.O. Box 524, Auckland Park,
Johannesburg 2006, South Africa.
Received: 5 August 2013 Accepted: 4 January 2015
References
1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the
30 years from 1981 to 2010. J Nat Prod. 2012;75:311–35.
2. Bhatt A, Naidoo Y, Nicholas A. An investigation of the glandular and non-
glandular foliar trichomes of Orthosiphon labiatus N.E.Br. [Lamiaceae]. New
Zeal J Bot. 2010;48:153–61.
3. Van Wyk B-E, Van Oudtshoorn B, Gericke N. Medicinal plants of south Africa.
Pretoria: Briza Publications; 2009.
4. Selvakkumar C, Gayathri B, Vinaykumar KS, Lakshmi BS, Balakrishnan A.
Potential anti-inflammatory properties of crude alcoholic extract of ocimum
basilicum L. in human peripheral blood mononuclear cells. J Heal Sci.
2007;53:500–5.
5. Singh S, Majumdar DK, Rehan HM. Evaluation of anti-inflammatory potential
of fixed oil of Ocimum sanctum (Holybasil) and its possible mechanism of
action. J Ethnopharmacol. 1996;54:19–26.
6. Masresha B, Makonnen E, Debella A. In vivo anti-inflammatory activities of
Ocimum suave in mice. J Ethnopharmacol. 2012;142:201–5.
Kapewangolo et al. Journal of Inflammation  (2015) 12:4 Page 12 of 137. Giday M, Teklehaymanot T, Animut A, Mekonnen Y. Medicinal plants of the
Shinasha, Agew-awi and Amhara peoples in northwest Ethiopia.
J Ethnopharmacol. 2007;110:516–25.
8. Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J.
Terpenoids: natural inhibitors of NF-kappaB signaling with anti-inflammatory
and anticancer potential. Cell Mol Life Sci. 2008;65:2979–99.
9. Girón N, Través PG, Rodríguez B, López-fontal R, Boscá L, Hortelano S, et al.
Supression of inflammatory responses by labdane-type diterpenoids. Toxicol
Appl Pharmacol. 2008;228:179–89.
10. Lyu S-Y, Park W-B. Production of cytokine and NO by RAW 264.7
macrophages and PBMC in vitro incubation with flavonoids. Arch Pharm
Res. 2005;28:573–81.
11. Kim D, Yamasaki Y, Jiang Z, Nakayama Y, Yamanishi T, Yamaguchi K.
Comparative study on modeccin- and phytohemagglutinin (PHA)-induced
secretion of cytokines and nitric oxide (NO) in RAW264.7 cells. Acta Biochim
Biophys Sin (Shanghai). 2011;43:52–60.
12. Hussein AA, Meyer JJM, Jimeno L. Bioactive diterpenes from Orthosiphon
labiatus and Salvia africana-lutea. J Nat Prod. 2007;293–95
13. Pedersen JA. Distribution and taxonomic implications of some phenolics in
the family Lamiaceae determined by ESR spectroscopy. Biochem Syst Ecol.
2000;28:229–53.
14. Škrovánková S, Mišurcová L, Machů L. Antioxidant activity and protecting
health effects of common medicinal plants. Adv Food Nutr Res.
2012;67:75–139.
15. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals
and antioxidants in oxidative stress-induced cancer. Chem Biol Interact.
2006;160:1–40.
16. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and
controversies. Nat Rev Microbiol. 2004;2:820–33.
17. Mirshafiey A, Mohsenzadegan M. The role of reactive oxygen species in
immunopathogenesis of rheumatoid arthritis. Iran J Allergy Asthma
Immunol. 2008;7:195–202.
18. Nam JS, Cho MH, Lee GT, Park JS, Ahn CW, Cha BS, et al. The activation of NF-
kappaB and AP-1 in peripheral blood mononuclear cells isolated from patients
with diabetic nephropathy. Diabetes Res Cinical Pract. 2008;81:25–32.
19. Wang J, Li G, Wang Z, Zhang X, Yao L, Wang F, et al. High glucose-induced
expression of inflammatory cytokines and reactive oxygen species in
cultured astrocytes. Neuroscience. 2012;202:58–68.
20. Checker R, Sandur SK, Sharma D, Patwardhan RS, Jayakumar S, Kohli V, et al.
Potent anti-inflammatory activity of ursolic acid, a triterpenoid antioxidant,
is mediated through suppression of NF-κB, AP-1 and NF-AT. PLoS One.
2012;7:e31318.
21. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol.
1997;9:240–6.
22. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases–regulating the immune
response. Nat Rev Immunol. 2007;7:202–12.
23. Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP. Cytokine
dysregulation, inflammation and well-being. Neuroimmunomodulation.
2005;12:255–69.
24. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides
induce the production of IL-17 in Th cells. J Immunol. 2000;165:6107–15.
25. Williams A, Steffens F, Reinecke C, Meyer D. The Th1/Th2/Th17 cytokine
profile of HIV-infected individuals: a multivariate cytokinomics approach.
Cytokine. 2013;61:521–6.
26. Paul AT, Gohil VM, Bhutani KK. Modulating TNF-alpha signaling with natural
products. Drug Discov Today. 2006;11:725–32.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J Immunol Methods.
1983;65:55–63.
28. Mirabelli CK, Johnson RK, Sung CM, Sung C, Faucette L, Muirhead K, et al.
Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties
of auranofin, a coordinated gold compound, in murine tumor models.
Cancer Res. 1985;45:32–9.
29. Fonteh PN, Keter FK, Meyer D. New bis(thiosemicarbazonate) gold(III)
complexes inhibit HIV replication at cytostatic concentrations: potential for
incorporation into virostatic cocktails. J Inorg Biochem. 2011;105:1173–80.
30. Abassi YA, Xi B, Zhang W, Ye P, Kirstein SL, Gaylord MR, et al. Kinetic cell-
based morphological screening: prediction of mechanism of compound
action and off-target effects. Chem Biol. 2009;16:712–23.
31. Atienzar FA, Tilmant K, Gerets HH, Toussaint G, Speeckaert S, Hanon E, et al.
The use of real-time cell analyzer technology in drug discovery: definingoptimal cell culture conditions and assay reproducibility with different
adherent cellular models. J Biomol Screen. 2011;16:575–87.
32. Marxen K, Vanselow KH, Lippemeier S, Hintze R, Ruser A, Hansen U.
Determination of DPPH radical oxidation caused by methanolic extracts of
some microalgal species by linear regression analysis of spectrophotometric
measurements. Sensors. 2007;7:2080–95.
33. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure
of “antioxidant power”: the FRAP assay. Anal Biochem. 1996;239:70–6.
34. Jimenez-Alvarez D, Giuffrida F, Vanrobayes F, Golay PA, Otting CC, Ardeau
AL, et al. High-throughput methods to assess lipophilic and hydrophilic
antioxidant capacity of food extracts in vitro. J Agric Food Chem.
2008;56:3470–7.
35. Apak R, Güçlü K, Özyürek M, Çelik SE. Mechanism of antioxidant capacity
assays and the CUPRAC (cupric ion reducing antioxidant capacity) assay.
Microchim Acta. 2007;160:413–9.
36. Kampa M, Nistikaki A, Tsaousis V, Maliaraki N, Notas G, Castanas E. A new
automated method for the determination of the total antioxidant capacity
(TAC) of human plasma, based on the crocin bleaching assay. BMC Clin
Pathol. 2002;16:1–16.
37. Woodside DG, Mcintyre BW. Inhibition of CD28/CD3-mediated
costimulation of naive and memory human T lymphocytes by intracellular
incorporation of polyclonal antibodies specific for the activator protein-1
transcriptional complex. J Immunol. 2014;161:649–58.
38. Fung FY, Li M, Breunis H, Timilshina N, Minden MD, Alibhai SMH. Correlation
between cytokine levels and changes in fatigue and quality of life in
patients with acute myeloid leukemia. Leuk Res. 2013;37:274–9.
39. Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology:
new insights into their cellular reduction. Biotechnol Annu Rev.
2005;11:127–52.
40. Masarik M, Gumulec J, Hlavna M, Sztalmachova M, Babula P, Raudenska M,
et al. Monitoring of the prostate tumour cells redox state and real-time
proliferation by novel biophysical techniques and fluorescent staining.
Integr Biol. 2012;4:672–84.
41. Gupta VK, Sharma SK. Plants as natural antioxidants. Nat Prod Radiance.
2006;5:326–34.
42. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, et al.
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new
therapeutic approach. J Clin Invest. 1998;101:783–94.
43. Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain. Nat
Rev Drug Discov. 2003;2:973–85.
44. Banno N, Akihisa T, Tokuda H, Yasukawa K, Higashihara H, Ukiya M, et al.
Triterpene acids from the leaves of Perilla frutescens and their anti-
inflammatory and antitumor-promoting effects. Biosci Biotechnol Biochem.
2004;68:85–90.
45. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines:
IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990;4:2860–7.
46. Krueger JG, Fretzin S, Suarez-Farinas M, Haslett PA, Phipps KM, Cameron GS,
et al. IL-17A is essential for cell activation and inflammatory gene circuits in
subjects with psoriasis. J Allergy Clin Immunol. 2012;130:145–54.
47. Von Bonin A, Rausch A, Mengel A, Hitchcock M, Krüger M, von Ahsen O,
et al. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new
concept for the therapy of inflammatory skin diseases. Exp Dermatol.
2011;20:41–7.
48. Hueber AJ, Asquith DL, Miller AM, Kerr S, Leipe J, Melendez AJ, et al. Cutting
edge: mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol.
2010;184:3336–40.
49. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-
microarray analysis of multiple sclerosis lesions yields new targets validated
in autoimmune encephalomyelitis. Nat Med. 2002;8:500–8.
50. Taylor MD, van der Werf N, Maizels RM. T cells in helminth infection: the
regulators and the regulated. Trends Immunol. 2012;33:181–9.
51. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis
factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70(1):i104–8.
52. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what
have we learned? Annu Rev Immunol. 2001;19:163–96.
53. Osborn L, Kunkelt S, Nabel GJ. Tumor necrosis factor-alpha and interleukin 1
stimulate the human immunodeficiency virus enhancer by activation of the
nuclear factor kB. Immunology. 1989;86:2336–40.
54. Beg AA, Finco TS, Nantermet PV, Baldwin Jr AS. Tumor necrosis factor and
interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a
mechanism for NF-kappa B activation. Mol Cell Biol. 1993;13:3301–10.
Kapewangolo et al. Journal of Inflammation  (2015) 12:4 Page 13 of 1355. Foletta VC, Segal DH, Cohen DR. Transcriptional regulation in the immune
system: all roads lead to AP-1. J Leukoc Biol. 1998;63:139–52.
56. Szekanecz Z, Shah MR, Pearce WH, Koch AE. Human atherosclerotic
abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-
gamma but not IL-2 and IL-4: the possible role for IL-6 and interferon-
gamma in vascular inflammation. Agents Actions. 1994;42:159–62.
57. Oxenkrug GF. Interferon-gamma-inducible kynurenines/pteridines inflammation
cascade: implications for aging and aging-associated psychiatric and medical
disorders. J Neural Transm. 2011;118:75–85.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
